Orphagen Pharmaceuticals announced today that the National Cancer Institute (NCI) has awarded a Phase I SBIR grant to the Company for development of a new class of small molecule drugs for the treatment of adrenocortical and prostate cancer. The objective of the studies is to demonstrate that the Company's proprietary small molecules are effective at physiological targets that will enhance therapy for these two devastating diseases. Adrenocortical...
The DNA promoter methylation inhibitor decitabine exhibited some antitumor properties in tests of adrenocortical carcinoma cells. The drug’s activity in recovering gene expression suggests that gene silencing on chromosome 11q13 may play a role in the rare malignancy’s origin.
“Decitabine reverses the classic epigenetic alteration, DNA promoter methylation,” researchers wrote. “It acts by removing inhibitory methyl groups from the...
Laparoscopic adrenalectomy has become the standard procedure for treating patents with adrenal masses. The purpose of this study was to evaluate the use of the LigaSure vessel closure...
OSI-906 in clinical trial for adrenocortical carcinoma
SCOTTSDALE, Ariz., Sept. 22 /PRNewswire-USNewswire/ -- TGen Clinical Research Services at Scottsdale Healthcare today announced the start of a clinical trial for a drug designed to combat adrenocortical carcinoma (ACC), a rare but deadly cancer that attacks the adrenal glands.
TCRS is a strategic alliance between the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare.
Gene-Expression Profiling Predicts Tumour Recurrence and Survival for Patients With Adrenocortical Tumours: Presented at ECE
By Chris Berrie
ISTANBUL, Turkey -- April 29, 2009 -- Routine analysis for the expression of 2 specific 2-gene combinations in patients with adrenocortical tumours can reliably predict the risk of tumour recurrence independent of pathology and can also predict the risk of death independent of tumour stage, according to research presented here at the...
